Coca

# Research Output: Coca

## Botanical Identity

**Accepted binomial:** *Erythroxylum coca* Lam. First published by Jean-Baptiste Lamarck in *Encyclopédie* 2: 393 (1786) [Ref 20].

**Family / Order:** Erythroxylaceae, Order Malpighiales. The family Erythroxylaceae contains approximately 240 species in four genera; *Erythroxylum* P. Browne is the largest, with ~230 species distributed primarily in tropical and subtropical regions [Ref 24].

**Discrepancy with brief:** The brief lists "no seed data" for family, genus/species, and native range. All three are now confirmed from primary sources.

**Native range:** Western South America — Bolivia, Brazil (North), Colombia, Ecuador, and Peru. The species grows primarily in the wet tropical biome and has been introduced to Assam, Cameroon, Caroline Islands, Guinea-Bissau, Gulf of Guinea Islands, Kazan-retto, and Tanzania [Ref 20].

**Infraspecific taxa:** Two recognized varieties:
- *E. coca* var. *coca* (Bolivian / Huánuco coca): adapted to the humid, tropical montane forest of the eastern Andes of Peru and Bolivia; most ancestral cultivated form [Ref 35].
- *E. coca* var. *ipadu* Plowman (Amazonian coca): cultivated in the lowland Amazon Basin, Peru and Colombia; genetically distinct with lower alkaloid content [Ref 35].

**Related cultivated species:** *Erythroxylum novogranatense* (Morris) Hieron, with two varieties — *novogranatense* (Colombian coca) and *truxillense* (Truxillo coca) — is a separate but closely related species adapted to drier conditions; together these four cultivated taxa represent all commercially alkaloid-bearing coca [Ref 35].

**Wild relatives:** Phylogenomic analysis (White et al. 2019 [Ref 2]) identified *E. gracilipes* and *E. cataractarum* as the closest wild relatives of the cultivated coca taxa. All four cultivated taxa fall within section *Archerythroxylum* O.E.Schulz, which lacks monophyly, complicating morphology-based classification.

**Cultivation status:** Exclusively cultivated; no significant wild harvest for commercial purposes. Major producing regions are Colombia (~253,000 ha, ~61% of global cultivation in 2023), Peru (~93,000 ha, 26%), and Bolivia (~31,000 ha, 13%) [Ref 43].

**Misidentification risks:** No published reports of toxic look-alikes. However, *E. novogranatense* is morphologically similar to *E. coca* and can be distinguished by leaf flavonoid chemotaxonomy: *E. coca* var. *coca* contains primarily eriodictyol O-conjugates, while *E. novogranatense* var. *novogranatense* contains luteolin and kaempferol O-conjugates (Johnson et al. 1997 [Ref via OpenAlex, DOI: 10.1515/znc-1997-9-1004]; **web_retrieved**, qualityTier: moderate).

**Biosynthesis localization:** Coca alkaloid biosynthesis occurs in the aerial portions of the plant (leaves), particularly in the palisade parenchyma and spongy mesophyll of young developing leaves. This contrasts with tropane alkaloid biosynthesis in Solanaceae, which occurs in the roots. Schmidt et al. (2015 [Ref 23]) identified cocaine synthase as a BAHD acyltransferase catalyzing the final esterification step (methylecgonine + benzoyl-CoA → cocaine).

---

## Alkaloid / Cannabinoid Profile

### Primary Alkaloid: Cocaine

**PubChem CID:** 446220 (api_verified)
**IUPAC name:** Methyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
**Molecular formula:** C₁₇H₂₁NO₄ | **MW:** 303.35 g/mol
**InChIKey:** ZPUCINDJVBIVPJ-LJISPDSOSA-N

**Concentration in plant material (dry weight):**
- *E. coca* var. *coca*: average 0.63% (range 0.23–0.96%)
- *E. coca* var. *ipadu*: 0.11–0.41% (lowest cocaine content of cultivated taxa)
- *E. novogranatense* var. *novogranatense*: average 0.77%
- Total alkaloid content (all taxa combined): 0.7–1.5% dry weight
- **Source note:** These figures derive from web-retrieved secondary summaries (ResearchGate table reference, Coca Wikipedia, Bauer 2019 [Ref 3]) and the Barnett et al. (1981 [Ref 32]) pharmacokinetics paper. ⚑ FLAG: No primary HPLC quantification study was retrieved via API. A CUNY thesis on HPLC/GC-MS quantification of coca alkaloids was identified but the PDF was not machine-readable. The concentration ranges above should be confirmed against a primary HPLC study before publication.

**Chemotype variation:** AFLP fingerprinting (Johnson et al. 2005 [Ref 35]) found clear genetic differentiation between *E. coca* and *E. novogranatense*, and between var. *coca* and var. *ipadu*. *E. coca* var. *ipadu* has significantly lower genetic diversity. Geographic origin, altitude, and soil conditions further modulate alkaloid expression within varieties.

### Key Metabolites and Minor Alkaloids

**Ecgonine** — PubChem CID 91460, C₉H₁₅NO₃, MW 185.22 g/mol. Core alkaloid skeleton of cocaine. Present as free ecgonine in leaves and as ecgonine methyl ester after hydrolysis of cocaine.

**Benzoylecgonine** — PubChem CID 448223, C₁₆H₁₉NO₄, MW 289.33 g/mol. Primary inactive urinary metabolite of cocaine; main analyte in drug testing.

**Norcocaine** — PubChem CID 644007, C₁₆H₁₉NO₄, MW 289.33 g/mol. Active N-demethylated metabolite; more toxic than cocaine; formed via CYP3A4 in human liver (LeDuc et al. 1993 [Ref 13]).

**Minor alkaloids present in leaves** (documented in genus-wide phytochemistry review, Lv et al. 2022 [Ref 24]):
- Cinnamoylcocaine (trans-cinnamoylcocaine) — second most abundant alkaloid in some accessions
- Truxillines (α-, β-, γ-truxilline)
- Tropacocaine (ecgonine benzoyl ester)
- Hygrine, cuscohygrine (pyrrolidine alkaloids)
- Ecgonidine
- Anhydroecgonine methyl ester (AEME) — pyrolysis product, a biomarker of smoked (crack) cocaine use
- 383 total compounds documented across 53 *Erythroxylum* species (Lv et al. 2022 [Ref 24])

**Preparation-dependent alterations:**
- Alkaline additive (lime, bicarbonate, *llipta*) during chewing increases cocaine extraction by ~4-fold; pH shift from ~5.5 to ~8 facilitates absorption from buccal mucosa
- Pyrolysis (smoking): converts cocaine → anhydroecgonine methyl ester (AEME); AEME is biomarker specific to smoked route [Ref 34]
- Aqueous extraction (coca tea): cocaine and other water-soluble alkaloids leach into infusion; cocaine content typically 2–5 mg per cup based on ~1–2 g dried leaves

---

## History & Ethnobotany

**Traditional/indigenous use:** *Erythroxylum coca* has been used by indigenous peoples of the Andes for thousands of years. The genus was in use before plant domestication in South America. Restrepo et al. (2019 [Ref 1]) note the two primary species (*E. coca* and *E. novogranatense*) were utilized specifically for tropane alkaloid content before formal domestication. Traditional uses include: chewing leaves with alkaline additive for stamina, hunger and fatigue suppression, altitude sickness mitigation, pain relief, and ritual/ceremonial purposes. Bauer (2019 [Ref 3]) reviews the cultural and traditional significance to Andean people as poorly recognized by health professionals. **⚑ FLAG: Traditional-use evidence for specific preparation methods relies heavily on ethnographic and anthropological accounts rather than controlled clinical data. These sections should be labeled as such.**

**Archaeological evidence:** Coca use has been documented archaeologically as far back as 8,000 years BP (Huaca Prieta site, Peru — per ethnobotanical literature; this claim is unverifiable via API and relies on unverifiable book/ethnographic sources. **⚑ FLAG for human review**).

**First scientific description:** *Erythroxylum coca* Lam., described by Jean-Baptiste Lamarck in *Encyclopédie Méthodique, Botanique* 2: 393 (1786). The genus name *Erythroxylum* derives from Greek *erythros* (red) and *xylon* (wood), referring to the reddish heartwood [Ref 20].

**European awareness:** Spanish chroniclers and conquistadors documented coca use in the 16th century. Knowledge of coca's stimulant properties spread slowly in Europe.

**Cocaine isolation:** Albert Niemann first isolated pure cocaine from coca leaves in 1860 as part of his doctoral work at the University of Göttingen. He reported the anesthetic effect on his tongue in his dissertation. Richard Willstätter later established the correct molecular structure (1898). **⚑ FLAG: Niemann 1860 is an unverifiable primary source (pre-digital); sourced from secondary accounts in Restrepo 2019 [Ref 1], Bauer 2019 [Ref 3], and Tsuchiya 2017 [Ref 38].**

**Medical history:**
- 1884: Carl Koller first used cocaine as a topical ophthalmic anesthetic; revolutionized eye surgery [Ref 38]
- 1884: Sigmund Freud published *Über Coca*, promoting cocaine for fatigue, depression, and morphine addiction (a position he later revised)
- 1884: William Halsted pioneered nerve block anesthesia using cocaine; subsequently became dependent
- 1886: Coca-Cola introduced using coca extract; decocainized since 1903
- 1914: Harrison Narcotics Tax Act (US): restricted non-medical cocaine distribution
- 1961: UN Single Convention on Narcotic Drugs: coca leaf and cocaine placed on Schedule I
- 1988: UN Convention Against Illicit Traffic in Narcotic Drugs reiterated controls on cocaine precursors
- 2012: Bolivia temporarily withdrew from the 1961 Convention and reacceded with a reservation explicitly allowing traditional coca leaf chewing [Ref 43 context; web_retrieved]
- 2025: WHO ECDD 48th meeting (October 2025) completed a comprehensive critical review of coca leaf; recommended maintaining Schedule I classification while acknowledging low public health risk from traditional use [Ref 30]

---

## Neuroscience & Mechanism

**Primary receptor targets:**

1. **Dopamine transporter (DAT) blockade** — cocaine binds to DAT and blocks dopamine reuptake, increasing synaptic dopamine in the nucleus accumbens and other mesolimbic regions. This is the primary mechanism of euphoria and reinforcement (Cooper et al. 2017 [Ref via PMID 28324454]; Heal et al. 2014 [Ref 7]).

2. **Norepinephrine transporter (NET) blockade** — increases synaptic norepinephrine; mediates cardiovascular stimulation (tachycardia, hypertension, vasoconstriction), arousal, and partly contributes to euphoriant effects.

3. **Serotonin transporter (SERT) blockade** — least potent of the three monoamine transporters; contributes to mood elevation and potentially to serotonergic toxicity in combination with serotoninergic drugs.

4. **Voltage-gated Na⁺ channel blockade** — membrane-stabilizing local anesthetic effect; responsible for the topical anesthetic utility in ENT procedures (Goprelto, Numbrino); contributes to arrhythmogenic potential and cocaine's lethality at high doses [Ref 5].

**Novel mechanistic hypothesis:** Heal et al. (2014 [Ref 7]) proposed that cocaine acts as a negative allosteric modulator (DAT "inverse agonist") to reverse the direction of DAT transport, inducing firing-dependent retro-transport of dopamine into the synaptic cleft, explaining why cocaine produces greater euphoria than other DAT inhibitors of equivalent potency.

**CNS pathway:** Mesolimbic dopamine system (VTA → nucleus accumbens); mesocortical dopamine system (VTA → prefrontal cortex). With repeated exposure, glutamatergic and opioidergic plasticity at NAc synapses contribute to compulsive use and relapse susceptibility (Wolf & Tseng 2012; Cooper et al. 2017).

**Pharmacokinetics by preparation route:**

| Route | Onset | Peak | Duration | Bioavailability |
|---|---|---|---|---|
| Coca leaf chewing | 15–45 min | 60–90 min | 2–4 h | Variable, low (slow buccal absorption) |
| Coca tea (oral infusion) | 30–60 min | ~60 min | 2–4 h | ~32–45% (oral); first-pass reduces cocaine |
| Intranasal (insufflation) | 3–5 min | 15–30 min | 45–90 min | ~60–75% |
| Smoked (freebase/crack) | <1 min | 3–5 min | 10–20 min | ~70–80% (pulmonary) |
| Intravenous | Seconds | 1–2 min | 20–40 min | 100% |
| Oral solution | 30–60 min | ~60–90 min | 2–4 h | 32–45% (Coe 2018 [Ref 33]) |

**Half-life:** Terminal plasma half-life is dose-dependent: Barnett et al. (1981 [Ref 32]) established t₁/₂(β) = 13.5 + 24.5 × dose (mg/kg) minutes; for typical recreational doses (1–3 mg/kg), this yields approximately 38–87 minutes. Commonly cited as ~0.5–1.5 hours in review literature.

**Norcocaine formation:** CYP3A4 is the primary enzyme responsible for N-demethylation of cocaine to norcocaine in human hepatic microsomes (LeDuc et al. 1993 [Ref 13]). Pellinen et al. (1996 [Ref 14]) demonstrated cocaine induces its own CYP metabolism with chronic dosing; CYP3A4 accounts for 70–90% of cocaine N-demethylase activity.

**Alcohol interaction — cocaethylene formation:** CES1 (hepatic carboxylesterase-1) and CYP3A4 catalyze transesterification of cocaine with ethanol to produce cocaethylene (Shang et al. 2022 [Ref 16]). Cocaethylene is more toxic than cocaine itself; extends duration of action. Route of cocaine administration affects cocaethylene yield: oral > IV > smoked (Herbst et al. 2011 [Ref 15]).

**Coca leaf chewing PK:** Barnett et al. (1981 [Ref 32]) specifically noted that blood cocaine concentrations from chewing coca leaves are unlikely to produce drug accumulation given the slow absorption rate (~8 min absorption half-life for mucosal routes at low doses), explaining why coca tea and leaf chewing produce qualitatively different and milder effects than insufflated or smoked cocaine.

**CYP interactions:** CYP3A4 mediates norcocaine formation; CYP inhibitors (ketoconazole, clarithromycin, ritonavir) could theoretically increase norcocaine formation and cocaine plasma exposure. ⚑ FLAG: No clinical case reports or formal PK interaction studies for cocaine + CYP3A4 inhibitors were identified. Flagging as mechanistic inference only.

**Blood-brain barrier:** Cocaine is highly lipophilic and crosses the BBB rapidly. In rat models, brain ECF/plasma AUC ratio was 2.02 ± 0.59 (Pan & Hedaya 1998), indicating preferential CNS distribution — key to its potent psychoactive effects even at relatively low plasma concentrations.

---

## Effects & Dose by Preparation

⚑ **NOTE:** No controlled human dose-finding studies specific to coca leaf chewing were retrieved. Dose data for coca preparations (leaf chewing, coca tea) come from the Bauer 2019 [Ref 3] review and Barnett 1981 [Ref 32] pharmacokinetics analysis. Published clinical dose-response data are primarily for refined cocaine HCl (intranasal, IV, smoked). All coca leaf-specific dose values should be flagged for human review.

### Coca Leaf Chewing (acullico / pijcheo)

**Preparation:** 20–60 g fresh leaves typically chewed with alkaline additive (lime [calcium hydroxide], sodium bicarbonate, or *llipta* [plant ash]). Alkaline pH shifts cocaine to free-base form, facilitating buccal mucosal absorption.

**Dose/effect:** Cocaine content per typical chew ~2–40 mg depending on leaf mass, alkaloid content of batch, and alkaline additive. Onset 15–45 min; effects mild stimulation, fatigue suppression, mild analgesia, appetite suppression. Bauer (2019 [Ref 3]) documents that coca leaf tea and chewing do not produce euphoria typical of refined cocaine at traditional use amounts.

**Duration:** 2–4 hours

**Onset:** 15–45 min (slow buccal absorption)

### Coca Tea (mate de coca / aguardiente de coca)

**Preparation:** Hot water infusion of ~1–2 g dried coca leaves; typically 2–5 mg cocaine per cup (web-retrieved; no primary HPLC study retrieved via API — ⚑ FLAG for human review).

**Effects:** Mild stimulation, alertness; used traditionally for altitude acclimatization. Clinical evidence for efficacy at altitude is limited and controversial (Bauer 2019 [Ref 3]). A 2025 case report documented RCVS following coca leaf tea consumption at high altitude (Del Brutto et al. 2025 [Ref 8]).

**Drug test implications:** Coca leaf chewing and tea consumption will produce positive urine drug tests for benzoylecgonine; this has important legal implications for travelers to Andean regions.

**Duration:** 2–4 hours; Onset: 30–60 min

### Intranasal Cocaine HCl (insufflation / "snorting")

**Doses:** Threshold ~5–10 mg; common 20–75 mg; heavy >100 mg per line. ⚑ FLAG: These dose ranges are derived from review literature synthesis (Bauer 2019, Lucyk 2022 [Ref 4]); no specific RCT dose-finding study retrieved for intranasal route.

**Onset:** 3–5 min | **Peak:** 15–30 min | **Duration:** 45–90 min

**Subjective effects:** Euphoria, stimulation, confidence, decreased appetite, talkativeness, grandiosity; vasoconstriction of nasal mucosa; local anesthesia. Romach et al. (1999) demonstrated D1/D5 receptor antagonism attenuates cocaine euphoria, confirming dopaminergic mediation.

**Adverse effects specific to route:** Rhinitis, nasal septum perforation, palatal perforation, saddle nose deformity with chronic use (Vergara et al. 2025 [Ref 36]; case after 12 years of use).

### Smoked Cocaine (crack / freebase)

**Preparation:** Cocaine HCl treated with baking soda and water, then dried ("cooked") to yield crack; or free-base prepared using solvent extraction. Freebase vaporizes at low temperature, can be inhaled.

**Doses:** 50–200 mg per hit (⚑ FLAG: web-retrieved estimate; no confirmed primary study).

**Onset:** <1 min | **Peak:** 3–5 min | **Duration:** 10–20 min

**Effect modifier:** Smoked route produces the most rapid brain delivery; Samaha & Robinson (2005 [Ref 11]) theorize that rapidly administered cocaine preferentially engages mesocorticolimbic circuits, promoting psychomotor sensitization and addiction. Cocaine-induced psychosis (CIP) is more prevalent with non-intranasal routes including smoking (Roncero et al. 2014 [Ref 27]).

**Preparation-specific adverse events:**
- "Crack lung": fever, hemoptysis, dyspnea within 48h of smoking; diffuse alveolar hemorrhage, interstitial pneumonia, pulmonary edema, eosinophilic infiltration (Mégarbane & Chevillard 2013 [Ref 28])
- Anhydroecgonine methyl ester (AEME) is a pyrolysis product and specific biomarker of smoked cocaine (Cone et al. 1997 [Ref 34])

### Intravenous Cocaine HCl

**Doses:** 0.2–1.0 mg/kg in controlled studies; street use highly variable.

**Onset:** Seconds | **Duration:** 20–40 min

**Bioavailability:** 100% | **Highest** addiction liability and cardiovascular risk profile.

**Route-specific risks:** IV injection introduces all needle-sharing risks (HIV, HCV, bacterial endocarditis, venous damage).

### Oral Cocaine HCl

**Bioavailability:** 32–45% (Coe et al. 2018 [Ref 33]); significant first-pass formation of norcocaine and benzoylecgonine.

**Historical context:** In the late 19th century, cocaine-containing preparations (Vin Mariani, early Coca-Cola) were taken orally. The slow absorption and first-pass metabolism explain why oral coca products produce comparatively mild effects.

**Effect modifiers across preparations:** Tolerant users require higher doses for equivalent effects; naive users more vulnerable to adverse cardiovascular effects; concurrent alcohol use increases toxicity through cocaethylene formation; body weight, hepatic function, plasma butyrylcholinesterase activity, and genetic CYP3A4 variants modulate cocaine metabolism.

---

## Safety & Toxicity

### LD50 and Acute Toxicity

No formal human LD50 is established. Cocaine intoxication is the most frequent cause of drug-related death reported by medical examiners in the United States (Lippi et al. 2010 [Ref 47]). Lethal blood cocaine concentrations typically exceed 1 mg/L; however, deaths have occurred at lower levels in the presence of cardiac predisposing conditions or co-ingested substances.

### Cardiovascular Toxicity (most clinically significant)

Cocaine is associated with a broad spectrum of cardiovascular complications (Lucyk 2022 [Ref 4]; Phillips et al. 2009 [Ref 5]; Maraj et al. 2010 [Ref 6]):

- **Myocardial infarction:** ~6% incidence in cocaine-associated chest pain presentations. Frequent cocaine users have a 7-fold higher risk of MI (Dugo et al. 2022 [Ref 32 cross-ref, PMID 32488581]). Mechanisms: coronary artery vasospasm, accelerated atherosclerosis, thrombus formation, Na⁺ channel blockade prolonging QT interval.
- **Arrhythmias:** Wide complex tachycardia, ventricular fibrillation, sudden cardiac death; mediated by Na⁺ channel blockade and sympathomimetic catecholamine surge.
- **Cardiomyopathy:** Dilated cardiomyopathy, myocarditis, left ventricular hypertrophy with chronic use.
- **Other:** Hypertensive crises, aortic dissection, aortic rupture, endocarditis (IV route), cerebral hemorrhage.
- **Treatment notes:** Beta-blockers **contraindicated** in cocaine-associated cardiovascular presentations (unopposed alpha stimulation worsens vasoconstriction); use benzodiazepines, nitroglycerin, calcium channel blockers, or phentolamine.

### Pulmonary Toxicity (crack cocaine-specific)

"Crack lung" syndrome: acute respiratory distress with fever, hemoptysis, dyspnea within 48h of inhalation; involves diffuse alveolar hemorrhage, interstitial pneumonia, and eosinophilic infiltration (Mégarbane & Chevillard 2013 [Ref 28]). Acute activation of circulating PMNs following cocaine inhalation contributes to lung injury (Baldwin et al. 1997, PMID 9118711). Alveolar permeability is increased in crack cocaine smokers.

### Neurological Complications

- **Stroke:** Both ischemic (vasospasm, accelerated atherosclerosis, thrombus) and hemorrhagic (hypertensive crises) strokes documented. Cocaine is a recognized independent stroke risk factor.
- **Cocaine-induced psychosis (CIP):** Prevalence up to 86.5% in some clinical populations. Paranoid delusions, visual and auditory hallucinations, paranoia. Risk factors: high dose, cumulative lifetime use, smoking/IV route, cannabis co-use, ADHD comorbidity, male sex (Roncero et al. 2014 [Ref 27]). Cocaine-induced postictal psychosis described as distinct entity (Chang et al. 2025, PMID 40936620).
- **RCVS:** Reversible cerebral vasoconstriction syndrome documented following coca leaf tea consumption at altitude (Del Brutto et al. 2025 [Ref 8]) — rare adverse event even from coca preparations.

### Nasal Complications (intranasal route-specific)

Chronic intranasal use causes progressive rhinitis, turbinate atrophy, septal perforation, palatal perforation, saddle nose deformity via ischemia and necrosis from vasoconstriction. Case documented after 12 years of use (Vergara et al. 2025 [Ref 36]).

### Hepatotoxicity

Norcocaine (CYP3A4 metabolite) is hepatotoxic; perivenular and midzonal necrosis documented in humans (Kanel et al. 1990 [Ref 46]). Cocaine induces its own hepatic CYP metabolism chronically (Pellinen et al. 1996 [Ref 14]). Cocaine-induced fulminant hepatic failure, rhabdomyolysis, and AKI documented as C-KLM syndrome (Kwentoh et al. 2023 [Ref 44]).

### Herb–Drug Interactions

1. **Ethanol (alcohol):** Most clinically significant interaction. Cocaethylene formed by CES1 + CYP3A4 transesterification; cocaethylene is more toxic than cocaine and has longer duration; increased cardiovascular risk (Herbst et al. 2011 [Ref 15]; Shang et al. 2022 [Ref 16]; Li et al. 2026 [Ref 22]). **Evidence level: multiple controlled clinical and animal studies. Confirmed.**

2. **Beta-adrenergic blockers:** Contraindicated; cocaine's alpha-agonist effects become unopposed → severe hypertension, coronary vasospasm. **Evidence level: clinical case series and pharmacological mechanism. Well-established.**

3. **MAOIs (monoamine oxidase inhibitors):** Theoretical risk of hypertensive crisis via amplified norepinephrine effect; serotonin syndrome risk with serotoninergic drugs. **Evidence level: pharmacokinetic mechanism only. ⚑ FLAG: No specific clinical case reports retrieved via API for cocaine + MAOI combination.**

4. **CYP3A4 inhibitors** (ketoconazole, clarithromycin, ritonavir): Would inhibit norcocaine formation AND potentially increase parent cocaine plasma levels by reducing clearance. **Evidence level: mechanistic inference from CYP3A4 characterization (LeDuc et al. 1993 [Ref 13]). ⚑ FLAG: No formal drug interaction PK study retrieved.**

5. **Tricyclic antidepressants:** Additive cardiovascular effects; both block Na⁺ channels; both have norepinephrine reuptake inhibitory effects. **Evidence level: pharmacological mechanism. ⚑ FLAG: No controlled clinical trial retrieved.**

### Levamisole Adulteration

Levamisole (a veterinary anthelmintic) contaminates ~69–80% of illicit cocaine in the United States (Buchanan & Lavonas 2012 [Ref 26]; Caldwell et al. 2012 [Ref 25]). First described as a cause of agranulocytosis in 2009. Clinical consequences include:
- Agranulocytosis (absolute neutrophil count → zero) with life-threatening infections
- ANCA-associated vasculitis with cutaneous involvement
- Leukoencephalopathy (multifocal)
- Acquired protein S deficiency

The reason for levamisole addition is not fully established; proposed reasons include bulking, mimicking cocaine's mucosal anesthetic effect, and possibly potentiating stimulant activity. Health professionals should consider levamisole-related agranulocytosis in cocaine users presenting with fever and neutropenia.

### Tolerance, Dependence & Withdrawal

**Tolerance:** Develops rapidly to the euphoriant effects with repeated dosing. Paradoxically, sensitization (not tolerance) occurs for stereotypy and psychosis risk with prolonged use — this differential neuroadaptation underlies cocaine use disorder.

**Dependence:** Primarily psychological; cocaine produces strong cravings and compulsive use. Physical dependence is present but less prominent than with opioids or alcohol. No approved pharmacotherapy exists for cocaine use disorder (Sinclair et al. 2026 [Ref 40]).

**Withdrawal timeline** (based on Gawin & Kleber model, confirmed by Medigue et al. 2025 [Ref 39] systematic review of sleep architecture):
- **Phase 1 — Crash (hours to 4 days post-cessation):** Dysphoria, fatigue, hypersomnia (increased total sleep time and REM rebound in first days [Ref 39]), increased appetite, reduced cocaine craving initially
- **Phase 2 — Withdrawal (1–10 weeks):** Anhedonia, anxiety, sleep disturbance, fatigue, intense cravings triggered by cues and environment; high relapse risk
- **Phase 3 — Extinction (months to years):** Gradual normalization; intermittent cue-triggered cravings persist for months; functional normalization of sleep architecture occurs but with high inter-subject variability [Ref 39]

⚑ FLAG: The Gawin & Kleber three-phase model (1986) is a widely cited unverifiable historical source (book chapter, pre-digital). The Medigue et al. 2025 systematic review [Ref 39] provides the most rigorous current evidence on the withdrawal timeline via objective sleep architecture data.

### Pregnancy and Pediatric Contraindications

Cocaine use in pregnancy is associated with increased placental abruption risk, adverse neonatal outcomes, and fetal CNS development effects (Kandhasamy et al. 2025 [Ref 42]). Crack/cocaine was associated with poor maternal outcomes including HELLP syndrome in a placental abruption cohort (Elkafrawi et al. 2020). **Cocaine is absolutely contraindicated in pregnancy.**

Pediatric CNS effects: prenatal cocaine exposure associated with functional brain connectivity alterations in neonates (Salzwedel et al. 2020, PMID 32779835).

### Vulnerable Populations

- **Cardiac disease:** Dramatically elevated risk of MI and sudden death
- **Psychiatric comorbidity:** Schizophrenia spectrum/psychosis risk amplified
- **Hepatic impairment:** Impaired cocaine and norcocaine metabolism increases toxicity
- **Pregnancy:** Absolute contraindication
- **Patients on beta-blockers, MAOIs, or TCAs:** High herb–drug interaction risk

---

## Harm Reduction

**Testing:** Illicit cocaine supply is heavily adulterated (levamisole ~69–80%; local anesthetics including procaine, benzocaine, lidocaine per Kudlacek et al. 2025 [PMID 41347157]). Fentanyl adulteration in cocaine is increasingly reported and toxicologically distinct (not reversed by benzodiazepines). Drug checking services should be recommended; fentanyl test strips and reagent testing available in harm reduction contexts.

**Route reduction:** Transition from smoked or IV cocaine to intranasal use substantially reduces cardiovascular risk, addiction progression, and pulmonary injury.

**Alcohol co-use:** Avoiding concurrent alcohol is a key harm reduction message; cocaethylene is more toxic, prolongs intoxication, and amplifies cardiovascular risk.

**Dosing intervals:** Rapid redosing ("binges") drives psychological escalation; spacing doses reduces compulsive redosing patterns.

**Cessation resources:** No FDA-approved pharmacotherapy for cocaine use disorder (as of 2026). Current evidence supports: cognitive behavioral therapy, contingency management, and treatment of comorbid psychiatric conditions. Suvorexant (dual orexin receptor antagonist, FDA-approved for insomnia) is under investigation for early withdrawal sleep disturbances (Webber et al. 2026, PMID 41950275).

**Emergency response:** Cocaine-associated chest pain should be evaluated as potential MI; avoid beta-blockers; use benzodiazepines for agitation; cool for hyperthermia; airway management for crack lung.

---

## Legal Status

### International
**1961 UN Single Convention on Narcotic Drugs:** Coca leaf and cocaine are both listed on Schedule I — the strictest tier, requiring limitation of production, trade, use, and possession to medical and scientific purposes. Cocaine itself is also in Schedule I of the 1961 Convention (not Schedule II as under US law).

**Article 49 exception:** Permitted traditional coca leaf chewing to continue in producing countries temporarily; this provision has been superseded for most signatories.

**2025 WHO ECDD Review:** The WHO Expert Committee on Drug Dependence (48th meeting, October 2025) completed a critical review of coca leaf. Recommendation: maintain Schedule I classification. Rationale: cocaine is easily and profitably extracted from coca leaf; sharp increases in global coca cultivation and cocaine production raise public health concerns. Acknowledged: traditional chewing and tea consumption do not pose major public health risks; cultural and therapeutic significance for indigenous peoples was recognized; existing national exemptions for traditional use remain [Ref 30].

### United States
- **Cocaine HCl:** DEA Schedule II — high potential for abuse, accepted narrow medical use (Goprelto [2017] and Numbrino [2020]: topical nasal anesthetic for adult diagnostic procedures and surgery only) [Ref 29].
- **Coca leaf:** DEA Schedule II
- **Crack cocaine / cocaine base:** No accepted medical use; effectively Schedule I for practical purposes
- **Possession without valid prescription:** Federal criminal offense; state penalties vary

### South America (Producing Countries)
- **Bolivia:** Coca legal for traditional use; 22,000 ha legally authorized cultivation (actual ~34,000 ha in 2024, per UNODC [Ref 43]); coca tea and chewing permitted; export of coca products strictly prohibited. Bolivia reacceded to 1961 Convention in 2013 with explicit reservation permitting traditional coca chewing.
- **Peru:** ~6 million traditional consumers; ~22,000 ha legal cultivation zone authorized by DEVIDA; coca tea, chewing, and certain food products legal; raw leaf and cocaine export prohibited.
- **Argentina:** Coca leaf and coca tea legal for cultural and traditional use in northern provinces; possession and sale of cocaine illegal.
- **Colombia:** Coca cultivation and trafficking illegal; largest producing country (~253,000 ha, 61% of global cultivation in 2023) [Ref 43].

### United Kingdom
Cocaine: **Class A** drug under the Misuse of Drugs Act 1971; maximum penalty: 7 years imprisonment + unlimited fine for possession; life imprisonment for supply. Coca leaf is also controlled [Ref 37].

### European Union
Cocaine is effectively Schedule I equivalent in all EU member states; no EU-level legalization exceptions. EU Drugs Agency (EUDA, formerly EMCDDA) reports cocaine as the second most commonly used illicit drug in Europe after cannabis.

### Australia
Cocaine is a **Schedule 8 controlled drug** under the Poisons Standard — prescription-only (very limited medical use); illegal to possess otherwise. Australian Capital Territory (ACT) enacted partial decriminalization of small amounts of all drugs including cocaine in October 2023 (health-based approach); criminal penalties remain at federal level and in all other states/territories [Ref 37].

---

## Clinical Trials

Relevant trials identified from ClinicalTrials.gov:

- **NCT02596022** (Completed, Phase 2): "The Effect of Glutamatergic Modulation on Cocaine Self-administration" — New York State Psychiatric Institute; conditions: Cocaine Dependence.
- **NCT01077024** (Completed, Phase 3): "Smoking-Cessation and Stimulant Treatment (S-CAST)" — University of Cincinnati; conditions: Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence.
- **NCT03090269** (Withdrawn, Phase 2): "Methylphenidate for Cocaine Dependence" — ANRS, France.
- **NCT05310773** (Completed): Couples Health CoOp Plus — RTI International; HIV and substance use.

No clinical trials specifically on coca leaf preparations (chewing, tea, nutritional extracts) were identified in ClinicalTrials.gov. ⚑ FLAG: Absence of clinical trials on coca leaf itself limits the evidence base for preparation-specific effects and safety data.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical Data Gaps

1. **⚑ Alkaloid concentration data (HPLC):** No primary HPLC or GC-MS alkaloid quantification study was retrieved via API. Concentration figures (E. coca var. coca ~0.63%; var. ipadu 0.11–0.41%; E. novogranatense ~0.77%; total alkaloids 0.7–1.5% DW) derive from secondary review sources (Bauer 2019 [Ref 3]) and web-retrieved summaries. A primary analytical chemistry study should be cited before publication.

2. **⚑ Coca leaf/tea dose ranges not verified against published primary source:** Dose figures for coca leaf chewing (20–60g leaf; 2–40mg cocaine) and coca tea (2–5mg cocaine/cup) were derived from secondary review literature and web summaries. No peer-reviewed dose-finding or pharmacokinetic study specifically for coca leaf preparations in humans was retrieved. These values require confirmation from a primary source.

3. **⚑ Cocaine crack dose ranges not verified:** Typical dose range for smoked crack cocaine (~50–200 mg per hit) is from web-retrieved secondary sources, not a primary controlled trial.

4. **⚑ Intranasal dose ranges not verified from primary source:** Threshold/common/heavy dose ranges for intranasal cocaine rely on Bauer 2019 review synthesis; not a controlled dose-finding trial.

5. **⚑ Nutritional/mineral content of coca leaves:** Published studies on the nutritional value of coca leaves (vitamins, minerals, fiber content cited in some ethnobotanical sources) were not retrieved via API. This information is potentially relevant to the article's coverage of traditional use but cannot be cited to a verified source at this time.

### Herb–Drug Interactions — Evidence Level Flags

6. **⚑ MAOI + cocaine interaction:** Flagged as theoretical/mechanistic only. No specific clinical case reports or formal PK interaction studies retrieved via API. Severity cannot be rated without clinical evidence.

7. **⚑ CYP3A4 inhibitors + cocaine:** Mechanistic inference only from LeDuc et al. 1993 [Ref 13]. No formal drug-drug interaction PK study identified.

8. **⚑ TCA + cocaine cardiovascular interaction:** Pharmacological mechanism is well-described but no controlled clinical PK study retrieved.

### Traditional Use — Human Review Required

9. **⚑ Traditional use as primary evidence:** The history and traditional use section relies substantially on ethnographic and anthropological accounts (Bauer 2019 [Ref 3]; Restrepo et al. 2019 [Ref 1]) rather than controlled clinical studies. This is flagged for human review as instructed.

10. **⚑ Archaeological evidence of coca use (8,000 BP):** Archaeological dating of coca use is an unverifiable book/monograph source not retrievable via API. Should be sourced to a primary archaeological publication.

11. **⚑ Niemann 1860 isolation:** Unverifiable primary source (pre-digital dissertation). Cited only via secondary accounts.

### Legal Status

12. **⚑ EU member state variation:** Individual EU country legal provisions for coca-containing food products and herbal preparations were not fully researched. Germany, Netherlands, and Spain have specific cases of prosecution over coca tea that may be relevant; flagged for human review.

### Miscellaneous

13. **⚑ Coca leaf and drug testing:** While it is established that coca leaf chewing/tea will produce positive urine tests for benzoylecgonine, no primary pharmacokinetic study of coca leaf preparation → urinary metabolite was retrieved. The Barnett 1981 paper [Ref 32] notes accumulation is unlikely from leaf chewing, but does not provide direct urine excretion data after leaf preparation consumption.

14. **⚑ Cocaine LD50 in humans:** No formally established human LD50 found in retrieved literature. The statement that lethal blood levels typically exceed 1 mg/L is from clinical toxicology review literature consensus but not formally cited to a single primary source.

15. **Wild relative misidentification risk:** No published reports of toxic look-alike misidentification with *E. coca* were found. This absence should be noted in the article.